Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: liver, addiction
- Who it enrolls
- age 18 Years to 70 Years; no BMI minimum stated; conditions: Non-alcoholic Fatty Liver Disease; Obesity
- Interventions
- Liraglutide; Orlistat
- Conditions
- Non-alcoholic Fatty Liver Disease; Obesity
- Phase and size
- Phase 4 · 102 participants
- Dates
- Start 2023-11-01
Primary completion 2024-10-31 - Sponsor
- Affiliated Hospital of Nantong University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Body weightThree months
- FABP4Three months
- BMIThree months
- lipid indicesThree months
- LSMThree months
- CAPThree months
02Eligibility
Who can take part
Inclusion Criteria: 1. Clinical diagnosis of Metabolic Associated Fatty Liver Disease(MAFLD); 2. Clinical diagnosis of Obesity. Exclusion Criteria: 1. Medicated Hepatitis and Viral Hepatitis; 2. Have severe hepatic or renal insufficiency; 3. have used any weight-loss drug; 4. History of severe gastrointestinal disorders; 5. Malignant tumors, autoimmune diseases, hematologic diseases; 6. Psychopath; 7. Women who are pregnant, breastfeeding or preparing for pregnancy;
03Change log
Registry changes
No changes recorded since the trial was added.